Abstract
It has been shown that gut dysbiosis can be associated with the development of type 2 diabetes mellitus (T2DM). Consequently, intervention with probiotics may be a useful approach to improve metabolic variables in diabetes. The present study aimed to evaluate the efficacy of L. paracasei HII01 on glycemia in T2DM patients. In a randomized, double-blind, placebo-controlled study, 50 participants were allocated to receive L. paracasei HII01 (50 × 109 CFU/day) or a placebo (corn starch 10 mg/day). Blood and fecal samples were assessed at baseline and at the end of the trial. After 12 weeks of intervention, fasting blood glucose level had significantly decreased in the probiotic group compared with the placebo group. Importantly, probiotic supplementation significantly decreased the plasma levels of LPS, TNF-α, IL-6 and hsCRP compared the placebo group. Additionally, an increase in beneficial bacteria and a decrease in pathogenic bacteria, which related to the improvement of SCFAs, was found following L. paracasei HII01 supplementation. These findings demonstrated that L. paracasei HII01 improved hyperglycemia and inflammatory markers by favorably modifying gut microbiota and subsequently ameliorating the leaky gut and endotoxemia, thereby suggesting a potential role as an adjuvant treatment in type 2 diabetes.
Highlights
Type 2 diabetes mellitus (T2DM) is one of the most common metabolic disorders in the world
It has been shown that an increase in the level of the pathogenic bacteria Clostridium, together with a reduction in the level of beneficial bacteria, namely Bacteroides, Bifidobacterium and Actinobacteria, was experienced by T2DM patients [28,29]
Even the abundance of those bacteria at baseline was not the same compared between the two groups but the resulted revealed that the percentage abundance of Bacteriodes, Lactobacillus, Faecalibacterium and Bifidobacterium increased after probiotic L. paracasei HII01 supplementation for 12 weeks in T2DM patients
Summary
Type 2 diabetes mellitus (T2DM) is one of the most common metabolic disorders in the world. In 2019, it was estimated that 463 million people worldwide had diabetes. Diabetes is an established major independent risk factor for several chronic diseases, such as ischemic heart disease, stroke and renal failure, which caused the death of 4.2 million people in 2019 [3]. These diabetic complications can be prevented or reduced by sustained control of blood glucose. Drugs in the treatment of diabetes can trigger several serious side effects. There is still a need for safer and effective hypoglycemic agents
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
